- Sharp acceleration in organic growth in the second quarter, up 4%
- Double-digit growth in emerging markets up 14%
- Sustained gains in North America
- Industrial application sales up 11%
- 2013 organic sales growth objective maintained
Marcy l'Etoile, France - July 18, 2013 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the six months ended June 30, 2013.
After remaining stable in the first quarter, sales rose by 4% on an organic basis to €395 million in the second three months of the year, led by rapid growth in emerging markets and in industrial applications.
As a result, sales ended the first half at €754 million, versus €750 million a year earlier, for a 2.1% increase at constant exchange rates and scope of consolidation.
Download
- Filename
- pr_biomerieux_q2_2013_sales_en.pdf
- Size
- 342 KB
- Format
- application/pdf